Table 2 Relative risk of COPD exacerbations stratified by severity in patients randomised to fluticasone and placebo groups over one year.
COPD exacerbations | Relative risk of COPD exacerbation for patients randomised to placebo or fluticasone (n = 260) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
Fluticasone (n = 128) | Placebo (n = 132) | Mean days of patient exposure | Exacerbation grouping | Incidence rate ratio | 95% confidence interval | adjusted p-value | ||||
Exacerbations while in trial | Unreported | 129 | Unreported | 116 | 235 in fluticasone, 179 in placebo | All | 1.11 | 0.91 | 1.36 | 0.298 |
Moderate | 224 | Moderate | 276 | |||||||
Severe | 21 | Severe | 22 | Moderate and severe only | 1.25 | 0.96 | 1.58 | 0.067 | ||
Total | 373 | Total | 413 | |||||||
Exacerbations while on randomised treatment | Unreported | 112 | Unreported | 99 | 371 in both groups | All | 1.48 | 1.17 | 1.86 | 0.001 |
Moderate | 158 | Moderate | 182 | |||||||
Severe | 9 | Severe | 12 | Moderate and severe only | 1.63 | 1.23 | 2.17 | 0.001 | ||
Total | 279 | Total | 293 | |||||||